Full Prescribing InformationPatient profiles
When PDE-5 inhibitors alone are inappropriate or ineffective, local vasodilation therapy may be considered for the treatment of ED.1
Below, you'll find a three hypothetical patient profiles of men seeking treatment for ED. In these examples, according to the AUA guideline, local vasodilation therapy using MUSE may be a clinically appropriate option.1
| Patient A: 68 years old; significant co-morbidities | ||
| Why MUSE may be clinically appropriate: | According to AUA guidelines, PDE-5 inhibitor therapy may be ineffective in some patients with diabetes and/or severe vascular disease.1 Regardless of his significant co-morbidities, he is motivated and seeking treatment for his ED, and he has a motivated partner as well. This is a candidate for MUSE therapy. | |
|---|---|---|
| Race: | Caucasian | |
| ED prescription history: | Multiple PDE-5 inhibitors | |
| Co-morbid conditions: | Insulin-dependent Type 2 diabetes (A1C > 9%),
obesity (BMI > 30kg/m2), hypertension (blood pressure > 150/90 mm Hg), cardiovascular disease (prior myocardial infarction) |
|
| Prior surgeries: | Coronary angioplasty | |
| Presentation: | Patient has been experiencing increasing difficulty with sexual intercourse in the last 7 to 9 months. Previous therapy with multiple PDE-5 inhibitors was ineffective. His primary care physician has deemed him healthy enough for sexual intercourse and has now referred him to a urologist for treatment of his ED. The patient has the support of his spouse. | |
| Patient B: 61-year-old has just finished treatment for prostate cancer | ||
| Why MUSE may be clinically appropriate: | In clinical trials, patients who have ED as a result of radical prostatectomy may be considered candidates for local vasodilation therapy such as MUSE, particularly after the failure of first-line treatments using PDE-5 inhibitors.1,2 | |
|---|---|---|
| Race: | Black | |
| ED prescription history: | Multiple PDE-5 inhibitors | |
| Co-morbid conditions: | Hypertension, Stage 2 prostate cancer | |
| Prior surgeries: | Radical prostatectomy | |
| Presentation: | Patient has been referred from his medical oncologist to his urologist following a complaint of ED. Two months prior, he finished postsurgical radiation therapy for Stage 2 prostate cancer. After unsuccessful trials of multiple PDE-5 inhibitors, the patient remains generally motivated to address his ED and has discussed his ED with his spouse. | |
| Patient C: 56 years old; does not tolerate PDE-5 inhibitors well | ||
| Why MUSE may be clinically appropriate: | Patient preference and a relatively young age can be factored into a decision to begin MUSE therapy.1 Patient preference may be driven in part by prior experience with undesired adverse events with PDE-5 inhibitors, as is the case with this patient.1 Additionally, this patient's aversion to injections or more dramatic procedures makes him an excellent candidate for MUSE therapy. | |
|---|---|---|
| Race: | Caucasian | |
| ED prescription history: | Multiple PDE-5 inhibitors | |
| Co-morbid conditions: | None | |
| Prior surgeries: | None | |
| Presentation: | Patient has been referred from his primary care physician to a urologist to address ED. Patient has gone through multiple rounds of oral PDE-5 inhibitor therapy with varying degrees of success, complaining of headaches and reporting 2 instances of syncope. Patient is physically active and in otherwise good health; he is unreceptive to alternative therapies, such as Bi-Mix and Tri-Mix injections and penile prostheses. | |
